KPTI Stock Overview
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.
Karyopharm Therapeutics Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.70|
|52 Week High||US$14.73|
|52 Week Low||US$4.00|
|1 Month Change||-13.12%|
|3 Month Change||-12.15%|
|1 Year Change||-21.54%|
|3 Year Change||-71.94%|
|5 Year Change||-49.13%|
|Change since IPO||-70.72%|
Recent News & Updates
Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Aug 07
Things Look Grim For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Today's DowngradeMay 05
Health Check: How Prudently Does Karyopharm Therapeutics (NASDAQ:KPTI) Use Debt?Mar 18
This Insider Has Just Sold Shares In Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Feb 20
Things Look Grim For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Today's DowngradeFeb 12
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Expected To Breakeven In The Near FutureFeb 01
Did You Miss Karyopharm Therapeutics' (NASDAQ:KPTI) Impressive 108% Share Price Gain?Jan 05
Need To Know: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Insiders Have Been Selling SharesDec 10
Is Karyopharm Therapeutics (NASDAQ:KPTI) Using Debt In A Risky Way?Nov 19
|KPTI||US Biotechs||US Market|
Return vs Industry: KPTI underperformed the US Biotechs industry which returned -8.6% over the past year.
Return vs Market: KPTI underperformed the US Market which returned -19.6% over the past year.
|KPTI Average Weekly Movement||10.9%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: KPTI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: KPTI's weekly volatility (11%) has been stable over the past year.
About the Company
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Karyopharm Therapeutics Inc. Fundamentals Summary
|KPTI fundamental statistics|
Is KPTI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|KPTI income statement (TTM)|
|Cost of Revenue||US$153.09m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.09|
|Net Profit Margin||-35.26%|
How did KPTI perform over the long term?See historical performance and comparison